FKFleur H.J. Kaptein

Fleur H.J. Kaptein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fleur H.J. Kaptein has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma

    by Fleur H.J. Kaptein, Tom van der Hulle, Sander J.E. Braken, Erik J. van Gennep, Jeroen T. Buijs, Mark C. Burgmans, Suzanne C. Cannegieter, Emma M.E. du Chatinier, Menno V. Huisman, Els L. van Persijn van Meerten, et al.


  • Open Access

    Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma

    by Fleur H.J. Kaptein, Milou A.M. Stals, Maaike Y. Kapteijn, Suzanne C. Cannegieter, Linda Dirven, Sjoerd G. van Duinen, Ronald van Eijk, Menno V. Huisman, Eva E. Klaase, Martin J.B. Taphoorn, et al.


  • Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction

    by Pragyi Shrestha, Saritha Adepu, Romain R. Vivès, Rana El Masri, Astrid Klooster, Fleur Kaptein, Wendy Dam, Stephan J. L. Bakker, Harry van Goor, Bart van de Sluis, et al.

    Significance Statement: Hypertension and elevated levels of LDL cholesterol (LDLc) are vital risk factors for cardiovascular disease (CVD) in patients with CKD. Although statins indisputably reduce plasma cholesterol levels, not all patients with renal disease benefit from them, making CVD the leading cause of CKD-related mortality. CKD induces hyperelongation of hepatic heparan sulfate (HS) chains from HS proteoglycans (HSPG), thereby increasing the HSPG–proprotein convertase subtilisin kexin type-9 (PCSK9) interaction. These changes associate with elevated LDLc levels, without affecting LDL-receptor expression. This study, using rat models, discloses a novel mechanism behind hypercholesterolemia in CKD with prospects for future investigation of the HSPG-PCSK9 interaction and development of novel heparin-related glycomimetics targeting interruption of HSPG-PCSK9 binding. Background: Dyslipidemia is an important risk factor in CKD. The liver clears triglyceride-rich lipoproteins (TRL) via LDL receptor (LDLR), LDLR-related protein-1 (LRP-1), and heparan sulfate proteoglycans (HSPGs), mostly syndecan-1. HSPGs also facilitate LDLR degradation by proprotein convertase subtilisin/kexin type 9 (PCSK9). Progressive renal failure affects the structure and activity of hepatic lipoprotein receptors, PCSK9, and plasma cholesterol. Methods: Uninephrectomy- and aging-induced CKD in normotensive Wistar rats and hypertensive Munich-Wistar-Frömter (MWF) rats. Results: Compared with 22-week-old sex- and strain-matched rats, 48-week-old uninephrectomized Wistar-CKD and MWF-CKD rats showed proteinuria, increased plasma creatinine, and hypercholesterolemia (all PPExt-1), revealed elongated HS chains in both CKD groups. Solid-phase competition assays showed that the PCSK9 interaction with heparin-albumin (HS-proteoglycan analogue) was critically dependent on polysaccharide chain length. VLDL binding to HS from CKD livers was reduced (P<0.05). Proteinuria and plasma creatinine strongly associated with plasma cholesterol, PCSK9, and HS changes. Conclusions: Progressive CKD induces hepatic HS elongation, leading to increased interaction with PCSK9. This might reduce hepatic lipoprotein uptake and thereby induce dyslipidemia in CKD. Therefore, PCSK9/HS may be a novel target to control dyslipidemia.


  • Open Access

    Prophylaxis and treatment of COVID-19 related venous thromboembolism

    by F.H.J. Kaptein, M.A.M. Stals, M.V. Huisman, F.A. Klok

    COVID-19 pneumonia has been associated with high rates of thrombo-embolic complications, mostly venous thromboembolism (VTE), which is thought to be a combination of conventional VTE and in situ immunothrombosis in the pulmonary vascular tree. The incidence of thrombotic complications is dependent on setting (intensive care unit (ICU) versus general ward) and the threshold for performing diagnostic tests (screening versus diagnostic algorithms triggered by symptoms). Since these thrombotic complications are associated with in-hospital mortality, all current guidelines and consensus papers propose pharmacological thromboprophylaxis in all hospitalized patients with COVID-19. Several trials are ongoing to study the optimal intensity of anticoagulation for this purpose. As for the management of thrombotic complications, treatment regimens from non-COVID-19 guidelines can be adapted, with choice of anticoagulant drug class dependent on the situation. Parenteral anticoagulation is preferred for patients on ICUs or with impending clinical deterioration, while oral treatment can be started in stable patients. This review describes current knowledge on incidence and pathophysiology of COVID-19 associated VTE and provides an overview of guideline recommendations on thromboprophylaxis and treatment of established VTE in COVID-19 patients.